3 ms·
Great question. Two problems with making a therapeutic antibody against seven KC. One is that we are not sure how good the seven KC antibodies are yet. We are w
by BiochemOki 7y ago
Great question. Two problems with making a therapeutic antibody against seven KC. One is that we are not sure how good the seven KC antibodies are yet. We are working on this. The problem there is that 7KC only differs from cholesterol by one atom. The other problem is that the 7KC that we are worried about is inside of cells, so our drug is designed to mechanically pull the seven KC out, which antibodies can't really do. Also, cyclodextrins are very well accepted by regulators, it's just that they are usually used as excipients rather than as Active Pharmaceutical Ingredients (APIs). There are two examples of cyclodextrin APIs already, however, one approved and one in late stage clinical trials.
- DrAwdeOccarim 7y agoCool, thanks for the reply. Are the approved use parenteral? Have you considered aptamers?
- BiochemOki 7y agoYes, we are looking at IV, as others have done already clinically. We aren't looking at aptamers or other clever ways of binding small toxic biomolecules. I hope that other groups are!
- DrAwdeOccarim 7y agoThis is a pretty interesting paper: https://stm.sciencemag.org/content/8/333/333ra50 https://stm.sciencemag.org/content/8/333/333ra50 Is there a chance that you are developing CD that target 7KC but at the end of the day, it dissolved chol-containing plaques inherently and that's where you'll derive the benefit from?